By Editorial Staff
In the complex, high-stakes world of oncology research, few organizations maintain as consistent a presence on the front lines as METAvivor. Led by President Kelly Shanahan, M.D., the organization is currently navigating a period of unprecedented activity, marked by a surge in research grant interest, high-level advocacy at global medical conferences, and a rapidly evolving regulatory landscape for metastatic breast cancer (MBC) treatments.
As the medical community grapples with funding uncertainties and the complexities of drug development, METAvivor remains a critical nexus between scientific innovation and the lived experience of those navigating a Stage 4 diagnosis.
The Landscape of Research: A Surge in Grant Applications
The current climate for scientific research is characterized by significant volatility, particularly regarding federal funding. This instability has created a ripple effect, driving an increased volume of researchers to private and non-profit organizations for support.
METAvivor’s Scientific Advisory Board (SAB) recently convened to review a staggering 200 Letters of Intent (LOIs) for the current grant cycle. This figure represents a 100% increase over typical submission volumes, signaling both a desperate need for resources and a robust pipeline of potential breakthroughs in metastasis research.
Dr. Stuart Martin, a veteran member of the SAB, highlighted the significance of this trend: “METAvivor is doing outstanding work to help metastasis research keep moving forward during this especially challenging time for research.”
The organization’s rigorous vetting process—which involves both scientific experts and Patient Advocate Reviewers (PARs)—is designed to ensure that funding is directed toward projects that are not only scientifically sound but also deeply impactful for the patient community. METAvivor is currently issuing a call to action for both scientists and patient advocates to join these review panels, emphasizing that the "patient voice" is the essential compass for clinical relevance.
Advocacy on the Global Stage: ASCO and Beyond
The fight against MBC is not confined to the laboratory; it is also waged in the conference halls where the future of oncology is debated. This week, the American Society of Clinical Oncology (ASCO) in Chicago serves as the epicenter of this advocacy.
Dr. Shanahan has been invited to deliver a keynote address on the "big stage," focusing on a critical, often overlooked aspect of clinical trial design: patient-centered endpoints. Her presentation, titled “How to design trials that are meaningful to people with cancer: ask us,” underscores the necessity of moving beyond traditional metrics to incorporate the quality-of-life priorities of those living with the disease.
Following her appearance at ASCO, Dr. Shanahan will transition to the Hormel Institute’s Global Cancer Consortium in Minnesota. There, she will continue to advocate for a "bigger table," urging researchers to integrate the expertise of patients directly into the research process. She will be joined by Dr. Danny Welch, an esteemed SAB member and pioneer in metastasis research, who will provide a keynote on the biological hallmarks of the disease.
Regulatory Hurdles and the "Live from Stage 4" Movement
The regulatory path for new cancer therapies is frequently fraught with complexity. A recent point of contention involves the Oncologic Drugs Advisory Committee (ODAC) and the potential for a treatment switch involving camizestrant for patients with ESR1 mutations.
METAvivor has been instrumental in disseminating information regarding these regulatory shifts through its Live from Stage 4 podcast series. This platform has emerged as a vital resource for "news by us, for us," providing a nuanced look at clinical developments.
The recent discussion regarding the FDA’s decision-making process—and the contrast with the European Medicines Agency’s (EMA) recommendation for camizestrant—highlights a critical disconnect between international regulatory bodies. As the FDA continues its review, the patient community remains in a state of watchful anticipation, underscored by the hope that these new technologies will soon be available to improve clinical outcomes for those with ER+, HER2- MBC.
A Wave of Progress: Recent FDA Approvals
Despite the challenges, May 2024 has been a month of notable progress in the oncology sector. The FDA has granted approvals that promise to reshape the standard of care for several patient populations:
- Vepdegestrant (Veppanu): Approved for ER+, HER2- MBC patients who possess an ESR1 mutation. This targeted therapy represents a significant advancement in addressing resistance mechanisms in endocrine-sensitive cancers.
- Datopotamab Deruxtecan (Dato-DXd): Received approval as a first-line treatment for patients with metastatic Triple-Negative Breast Cancer (TNBC) who are not candidates for immunotherapy.
- Enhertu (Trastuzumab Deruxtecan): The FDA has expanded its indications into the early-stage HER2+ setting. This strategic move is intended to lower the risk of recurrence, potentially preventing the progression to metastatic disease for many patients.
These approvals, while individual, contribute to a larger, more hopeful narrative: the transition of MBC from a terminal diagnosis to a manageable, chronic condition.
Chronology: A Season of High-Stakes Activity
- Early May: The FDA announces a flurry of approvals for metastatic breast cancer, including vepdegestrant and dato-DXd.
- Mid-May: METAvivor’s Scientific Advisory Board meets to review 200 research grant applications, noting a 100% year-over-year increase in submissions.
- Late May: Dr. Kelly Shanahan, M.D., prepares for the ASCO conference in Chicago to speak on patient-centered trial design.
- Late May/Early June: METAvivor engages in high-level discussions via the Live from Stage 4 podcast regarding the regulatory status of camizestrant and the role of the FDA’s ODAC.
- Mid-June: Participation in the Hormel Institute’s Global Cancer Consortium in Austin, Minnesota, to bridge the gap between researchers and the patient community.
Implications for the Future of MBC Care
The work being done by METAvivor and its partners carries significant implications for the future of medicine. By demanding that the "patient voice" be included in the design of clinical trials, the organization is effectively changing the metrics of success.
Why Patient-Centered Endpoints Matter
Historically, clinical trials have focused heavily on progression-free survival (PFS) and overall survival (OS). While these remain the gold standards for efficacy, they do not always capture the daily burden of treatment—the side effects, the impact on quality of life, and the practicalities of long-term care. By advocating for "meaningful" trials, METAvivor is pushing for data that reflects the reality of living with cancer.
The Role of Advocacy in Research Funding
The surge in grant applications highlights a fundamental issue: private and non-profit funding is becoming the lifeblood of metastatic research. As federal funding fluctuates, organizations like METAvivor provide the stability necessary for high-risk, high-reward research to continue. The reliance on donations is not merely a fundraising strategy; it is a necessity for the survival of the research ecosystem.
Regulatory Transparency
The ongoing dialogue surrounding the FDA and EMA’s differing stances on camizestrant underscores the need for greater transparency and speed in the drug approval process. Patients are, quite literally, waiting on these decisions. The ability of patient advocacy groups to interpret and explain these complex regulatory moves to the public is a crucial service that empowers patients to make informed decisions about their own care.
Conclusion: A Fragile but Hopeful Path
Life with metastatic breast cancer is often described as a series of sudden changes—much like the weather in Tahoe, where Dr. Shanahan’s office overlooks a landscape that can shift from a sunny 70 degrees to a winter snowstorm in mere hours.
As the oncology community moves through this busy spring, the outlook is one of cautious optimism. Between the promising studies presented at ASCO, the influx of new, targeted therapies, and a more empowered, educated patient base, the landscape of MBC is undeniably changing. However, as Dr. Shanahan noted, the work is far from over. Whether it is through the rigorous review of grant applications or the high-level advocacy conducted on the stage of the world’s largest cancer conferences, the goal remains singular: to extend and improve the lives of those living with stage 4 cancer.
For the community, the message is clear: the table is growing. The challenge now is to ensure that the research, the regulation, and the treatment options keep pace with the urgent, undeniable needs of those waiting for their next scan, their next treatment, and their next tomorrow.
About the Author
